Abstract | RATIONALE:
Myocardial infarction and stroke are leading causes of morbidity/mortality. The typical underlying pathology is the formation of thrombi/emboli and subsequent vessel occlusion. Systemically administered fibrinolytic drugs are the most effective pharmacological therapy. However, bleeding complications are relatively common and this risk as such limits their broader use. Furthermore, a rapid non-invasive imaging technology is not available. Thereby, many thrombotic events are missed or only diagnosed when ischemic damage has already occurred. OBJECTIVE: Design and preclinical testing of a novel ' theranostic' technology for the rapid non-invasive diagnosis and effective, bleeding-free treatment of thrombosis. METHODS AND RESULTS: CONCLUSIONS: We describe a novel theranostic technology enabling simultaneous diagnosis and treatment of thrombosis, as well as monitoring of success or failure of thrombolysis. This technology holds promise for major progress in rapid diagnosis and bleeding-free thrombolysis thereby potentially preventing the often devastating consequences of thrombotic disease in many patients.
|
Authors | Xiaowei Wang, Yannik Gkanatsas, Jathushan Palasubramaniam, Jan David Hohmann, Yung Chih Chen, Bock Lim, Christoph E Hagemeyer, Karlheinz Peter |
Journal | Theranostics
(Theranostics)
Vol. 6
Issue 5
Pg. 726-38
( 2016)
ISSN: 1838-7640 [Electronic] Australia |
PMID | 27022419
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fibrinolytic Agents
- Single-Chain Antibodies
|
Topics |
- Animals
- Bleeding Time
- Blood Platelets
(immunology)
- Disease Models, Animal
- Fibrinolytic Agents
(administration & dosage, pharmacokinetics)
- Mice
- Microbubbles
- Single-Chain Antibodies
(immunology, pharmacokinetics)
- Theranostic Nanomedicine
(methods)
- Thrombolytic Therapy
(methods)
- Thrombosis
(diagnostic imaging, therapy)
- Treatment Outcome
- Ultrasonography
(methods)
|